EP0125252A1 - Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines - Google Patents
Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitaminesInfo
- Publication number
- EP0125252A1 EP0125252A1 EP83903370A EP83903370A EP0125252A1 EP 0125252 A1 EP0125252 A1 EP 0125252A1 EP 83903370 A EP83903370 A EP 83903370A EP 83903370 A EP83903370 A EP 83903370A EP 0125252 A1 EP0125252 A1 EP 0125252A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- combination
- use according
- long
- nicotinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to the new use of a single vitamin or a combination of different vitamins in the long-term treatment and / or prophylaxis of rheumatic diseases, and a method for the long-term treatment and / or prophylaxis of rheumatic diseases.
- Rheumatic diseases are widespread diseases. In the United States alone, approximately 30 million people suffer from arthritis, see TIME No. 33, page 41, from August 16, 1982. In the "Bulletin on the Rheumatic Diseases", Vol. 32, No. 1, (1982), page 1, published by the Arthritis Foundation, 3400 Peachtree Road, NE Atlanta, Georgia 30326 describes known treatments for rheumatoid arthritis.
- the present invention relates to the new use of a single vitamin or a combination of different vitamins in the long-term treatment and / or prophylaxis of rheumatic diseases, in particular those of an inflammatory and degenerative nature which affect joints, muscles, tendons and other parts of the musculoskeletal system.
- rheumatic diseases in particular those of an inflammatory and degenerative nature which affect joints, muscles, tendons and other parts of the musculoskeletal system.
- diseases are arthritis, chronic polyarthritis, primary polyarthritis and general arthritis, especially chronic and / or acute arthritis.
- the word "polyarthritis" has the meaning of a collective term for all possible manifestations of this disease (s) and their aetiology (s), be it rheumatoid arthritis, primary chronic polyarthritis, osteoarthritis or any of the over 100 other types and variants, symptoms and syndromes of this disease. In the following, the generic and collective term of polyarthritis is used.
- Long-term treatment can be done in any way; systemic, periiniectio and topical administration are preferred, and oral administration is most preferred.
- the active substances acting as anti-rheumatic agents are administered orally and / or by iniectio in a dosage of about 0.25-2 mg / kg body weight per day, preferably 0.5-1 mg / kg / day, although larger or smaller doses can also be used are and can easily be determined by a specialist, for example a doctor.
- the amounts of the individual vitamins can be varied.
- the dose can be taken as a single dose or divided into several doses.
- Usual forms of use such as capsules, coated tablets or tablets, come into consideration as the form of administration for the preferred oral administration. Such use forms can be produced in the customary manner.
- the treatment of the patient according to the invention takes place over the long term.
- the term "long-term” generally depends on the degree of the disease to be treated, the general condition of the patient, his body weight and his age.
- One skilled in the art can easily find out how long the treatment must continue until improvement or complete healing.
- a daily administration of the active ingredient or combination of active ingredients can be interrupted for a certain period of time, for example 1 week or 1 month or longer, and the administration mentioned can then be carried out in the same, increased or reduced manner. Mass to be continued.
- a preferred long-term treatment lasts at least 5 months, in particular at least 6 months, preferably 1 year, more preferably at least 2 years. In some cases, it has been shown that it is extremely beneficial for the patient to be treated if the long-term treatment is lifelong.
- the long-term, regular, continuous, uninterrupted and daily use of an active substance or combination of active substances to be used according to the invention is particularly preferred in order to cure and / or inhibit and / or prevent (prophylaxis) a rheumatic disease, especially polyarthritis in general and primarily chronic polyarthritis.
- the vitamin or the vitamins preferably belong to the vitamin B complex; for a definition of this The term is referred to, for example, the "chemistry lexicon" mentioned above.
- the vitamin or the vitamin combination can be combined with at least one mineral and / or at least one trace element and / or at least one additive, in particular carrier materials, antioxidants, bacteriostatics.
- Kryptoxanchin (ß-Hydroxy-ß-carotin) Echincnon (4-Oxo-ß-carotin) Citroxanthin (Mutatochrome; ß-Carotinoxyd) Myxoxznchin
- all-trans vitamin A 1 all-trans-3,7-dimethyl-9- (2 ', 6', 6'-trimethyl-l'-cyclohexen-l'-yl) -2,4,6,8 -nonatetraen-l-ol
- Pantothenyl alcohol panthenol
- Pteroylglutamic acid vitamin B c Vitamin M Pteroylglutamic acid vitamin B c Vitamin M.
- Vitamin B 12 factors (cobalamins) have been isolated and displayed. They differ from each other by different nucleotide fractions and have different biological activities. Vitamin B 12 is largely obtained from residues from cultures of Streptomyces griseus and similar organisms. vitamin C
- Vitamin D 2 Ergocalciferol
- Vitamin D 3 cholecalciferol
- vitamin D group vitamin D 1 molecular compound of vitamin D 2 with lumisterin 2 (Radiation product of ergosterol). Does not occur in nature.
- Vitamin D 4 radiation product of 22,23-dihydroergosterol
- Vitamin D 5 radiation product of 7-dehydrositosterol
- Vitamin D 6 radiation product of 7-dehydrostigmasterol
- Vitamin D 7 radiation product of 7-dehydrocamposterol (isomer to 22,23-dihydroergosterol).
- Vitamin E Vitamin E.
- Vitamin E is the group name for all tocopherols, which are determined by the number and position of the methyl groups on the hydroxychroman ring, partly. also differ by the presence of double bonds in the phytyl side chain. In general, vitamin E is understood to mean the ⁇ -tocopherol or its acetate, which has the greatest biological effectiveness of all tocopherols. Chemical names:
- ⁇ -tocopherol 2,5,7,8-tetramethyl-2- (4 ', 8', 12'-trimethyl-dodecyl) -chroman-6-ol or 5,7,8-trimethyltocol ⁇ -tocopherol: 5, 8-dimethyltocol ⁇ -tocopherol: 7,8-dimethyltocol ⁇ -tocopherol: 8-monomethyltocol ⁇ -tocopherol: 2-farnesyl-2,5,8-trimethylchroman-6-ol ⁇ -tocopherol: 2-farnesyl-2,5, 7,8-tetramethylchroman-6-ol ⁇ -tocopherol: 7-monomethyltocol
- Active ingredients The essential factors of the vitamin B complex in pure form and in therapeutically coordinated proportions.
- 1 ml Tr. contains 1.14 g carbohydrates, equivalent to 4.7 kcal, 1 Forte-Dragée 270 mg, equivalent to 1.1 kcal, and 5 ml syrup 4.02 g, equivalent to 16.5 kcal.
- Vitamin B complex with vitamin C tablettes or with vitamin C and calcium (effervescent tablets) composition
- 1 effervescent tobacco contains 704 mg carbohydrates, equivalent to 2.9 kcal; any effervescent tobacco. also contains approx. 230 mg Na (corresponding to 0.6 g NaCl). In the case of a strictly low-NaCl diet, it is therefore advisable to prescribe tablets instead of effervescent tabs.
- 1 effervescent tablet contains 891 mg carbohydrates, equivalent to 3.6 kcal; also 300 mg Na (corresponding to approx. 0.7 g NaCl); 1 Dr. 350 mg, corresponding to 1.4 kcal. For patients on a diet low in NaCl, it is therefore advisable to prescribe capsules. or Dr. instead of the shower tabi.
- the method according to the invention for long-term treatment and / or prophylaxis of rheumatic diseases is characterized in that a single vitamin or a combination of various vitamins which are variable in amount is administered to a patient.
- the preferred active ingredient combinations specified above are preferably administered orally and / or by iniectio.
- the new use according to the invention and the method according to the invention are used both in human and in veterinary medicine; e.g. e.g. in humans and warm-blooded animals such as horses, cattle, cows, dogs, cats, etc.
- Person A is approx. 153 cm tall and has a delicate shape. She was a non-smoker all her life, but was always a "good eater", carnivore, who only had a moderate amount of alcohol - a glass of wine and only with meals. Their weight must have been approximately 47 kg in 1972. It must have been around 1972, 10 years ago, when she started to complain of "rheumatic pain" in the right shoulder and the right knee. Person A has been a widow since 1948 and has the habit of indulging in her love for the city by walking countless (approx. 10-12 km) kilometers a day. The onset of pain in the right knee automatically reduced these extensive daily city trips. The disease only slowly and gradually became manifest and dragged on for years.
- her polyarthritis developed slowly, but progressively, which was easy to observe because person A was examined at very regular intervals (once a week).
- Polyarthritic diseases did not occur either in the father or in the sisters of person B. In person B's mother, polyarthritic diseases were only found at an advanced age. A first indication of possible polyarthritis appeared in person B about 9 years ago, i.e. in 1973: a singular, medium-hard and quite painful swelling of the middle joint on the index finger to the right of great persistence (it exists today, but thanks to " Combination II "treatment, only a small part, but painless). No special attention was paid to the phenomenon. About 3 years ago, in 1979, it could be observed that person B also stiffened in the morning. Fingers started to wake up.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines dans le traitement à long terme et/ou la prophylaxie de maladies rhumatismales. Lors du traitement à long terme et/ou de la prophylaxie de maladies rhumatismales, on administre à un patient une vitamine unique ou une combinaison de diverses vitamines.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH6682/82 | 1982-11-16 | ||
CH668282 | 1982-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0125252A1 true EP0125252A1 (fr) | 1984-11-21 |
Family
ID=4313378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83903370A Withdrawn EP0125252A1 (fr) | 1982-11-16 | 1983-11-16 | Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines |
Country Status (4)
Country | Link |
---|---|
US (1) | US4619829A (fr) |
EP (1) | EP0125252A1 (fr) |
JP (1) | JPS59502024A (fr) |
WO (1) | WO1984001899A1 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3416209A1 (de) * | 1984-05-02 | 1985-11-21 | Mohamed Roshdy Dr Ismail | Zubereitungen zur behandlung von augen |
JPS61183219A (ja) * | 1985-02-07 | 1986-08-15 | Takeda Chem Ind Ltd | 発泡組成物の製造法 |
CA1218303A (fr) * | 1985-08-21 | 1987-02-24 | Larry Barron | Compose pour la stimulation temporaire de la production d'urine |
AU587863B2 (en) * | 1985-10-07 | 1989-08-31 | Basf Aktiengesellschaft | Vitamin-containing granules and production thereof |
WO1988004927A1 (fr) * | 1986-12-31 | 1988-07-14 | Davirand, Inc. | COMPOSITIONS ET FORMULATIONS CONTENANT DE l'ACIDE FOLIQUE ET MODE D'UTILISATION ET PROCEDE DE PREPARATION DE CELLES-CI |
NO168563C (no) * | 1987-09-28 | 1992-03-11 | Collett Marwell Hauge As | Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv |
US5368851A (en) * | 1988-05-16 | 1994-11-29 | Chief Resources Limited | Composition containing divalent manganese ion and method for preparing the same |
JPH0773597B2 (ja) * | 1988-05-16 | 1995-08-09 | 俶将 猪狩 | 脱臭剤組成物 |
US5021424A (en) * | 1989-06-01 | 1991-06-04 | Lawton Wall Jennylyn | Vitamin composition for treatment of flea infestation in animals |
DE3927810A1 (de) * | 1989-08-23 | 1991-02-28 | Basf Ag | Riboflavingranulate |
FR2653117A1 (fr) * | 1989-10-13 | 1991-04-19 | Medafor | Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant. |
CA2044162A1 (fr) * | 1989-10-13 | 1991-04-14 | Jacques Borg | Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant |
US5167953A (en) * | 1990-06-21 | 1992-12-01 | Trustees Of Boston University | Compositions comprising tachysteral and the use thereof to provide vitamin D |
US5194248A (en) * | 1990-06-21 | 1993-03-16 | Trustees Of Boston University | Compositions comprising vitamin D analog precursors and the use thereof |
US5395829A (en) * | 1990-10-04 | 1995-03-07 | Trustees Of Boston University | Compositions comprising vitamin D lumisterol analog precursors |
GB2252905B (en) * | 1991-02-11 | 1995-05-10 | Leung Lit Hung | An agent for correcting a deficiency of androgenic steroids |
US5512277A (en) * | 1991-05-15 | 1996-04-30 | Kao Corporation | Keratotic plug remover |
NZ244270A (en) * | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
WO1993013660A1 (fr) * | 1992-01-06 | 1993-07-22 | Health Maintenance Programs, Inc. | Composition contenant un anti-oxydant pharmaceutiquement actif et son procede d'utilisation dans la prevention et le traitement d'une restenose apres angioplastie |
US5358720A (en) * | 1993-10-22 | 1994-10-25 | Koppel Richard M | Treatment of arthritic conditions |
DE4436127A1 (de) * | 1994-09-27 | 1996-03-28 | Deutsches Rheumaforschungszent | Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
ATE293883T1 (de) * | 1996-01-16 | 2005-05-15 | Ronald J Sokol | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen |
US5759559A (en) * | 1997-05-05 | 1998-06-02 | Fitzjarrell; Edwin A. | Method and composition for treating acne |
US5989523A (en) * | 1998-03-20 | 1999-11-23 | Fitzjarrell; Edwin A. | Topical spray for treating acne containing niacinamide and NaPCA |
US6106818A (en) * | 1998-04-27 | 2000-08-22 | Revlon Consumer Products Corporation | Method for removing dead surface cells, dirt, oil, and blackheads from the skin and related compositions and articles |
IT1306141B1 (it) * | 1999-05-17 | 2001-05-30 | Giampiero Valletta | Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche. |
US6432430B1 (en) | 2000-11-17 | 2002-08-13 | Edwin Fitzjarrell | Exfoliating scrub with niacinamide |
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
US6849613B2 (en) | 2001-08-29 | 2005-02-01 | Kedar N. Prasad | Multiple antioxidant micronutrients |
US7449451B2 (en) * | 2001-08-29 | 2008-11-11 | Premier Micronutrient Corporation | Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks |
US7560123B2 (en) * | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US8617617B2 (en) * | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
US6814983B2 (en) * | 2002-12-10 | 2004-11-09 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US20040137080A1 (en) * | 2003-01-13 | 2004-07-15 | Cremisi Henry D. | Multivitamin regimen for renal patients |
WO2004093824A2 (fr) * | 2003-04-08 | 2004-11-04 | Fairfield Clinical Trials, Llc | Supplementation nutritionnelle peri-operationnelle et peri-interventionnelle |
US8101587B2 (en) * | 2004-08-12 | 2012-01-24 | Everett Laboratories, Inc. | Kits for nutrition supplementation |
US20060182729A1 (en) * | 2005-02-17 | 2006-08-17 | Prasad Kedar N | Combat/training antioxidant micronutrient formulation and method of administration |
US7436412B2 (en) * | 2005-08-24 | 2008-10-14 | Qualcomm Incorporated | Graphics engine with efficient interpolation |
US20070190126A1 (en) * | 2006-02-14 | 2007-08-16 | Stuart Daniel M | Method for treating generalized and focal peripheral neuropathies |
FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
US8906966B2 (en) | 2006-07-13 | 2014-12-09 | Paul Sherwood | Medicaments containing panthenol |
WO2009010707A1 (fr) * | 2007-07-13 | 2009-01-22 | Prototype Bioforum Limited | Compositions pharmaceutiques injectables contenant du panthénol |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US20150024089A1 (en) * | 2012-04-19 | 2015-01-22 | Forza Technologies Llc | Natural nutritional supplements |
WO2014143192A1 (fr) * | 2013-03-13 | 2014-09-18 | Noglo Llc | Réduction ou prévention de réaction à l'alcool avec des compléments alimentaires |
US20140073598A1 (en) * | 2012-09-11 | 2014-03-13 | Jaymac Pharmaceuticals Llc | Multiple folate formulation and use thereof |
US10499682B2 (en) | 2014-08-25 | 2019-12-10 | New Age Beverage Corporation | Micronutrient formulation in electronic cigarettes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1261995A (en) * | 1917-11-03 | 1918-04-09 | Charles F Ampt | Food product and method of preparing same. |
US2816854A (en) * | 1953-05-26 | 1957-12-17 | Ralph H Gross | Nutrition aid |
US4206222A (en) * | 1977-06-23 | 1980-06-03 | Societe Civile Particuliere De Brevets Suffren | Method for preparing a substance having properties against collagen diseases and products obtained |
US4200647A (en) * | 1977-12-21 | 1980-04-29 | Hoffmann-La Roche Inc. | Vitamin A compositions to treat rheumatic disease |
JPS5626820A (en) * | 1979-08-10 | 1981-03-16 | Chugai Pharmaceut Co Ltd | Immunosuppressing agent |
IT1141651B (it) * | 1980-06-24 | 1986-10-08 | Giuseppe Riva | Procedimento per la stabilizzazione di vitamine |
NZ195881A (en) * | 1980-12-19 | 1984-08-24 | W Lysaght | Pharmaceutical compositions containing cobalt compounds |
US4386072A (en) * | 1981-06-26 | 1983-05-31 | Horrobin David F | Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor |
-
1983
- 1983-11-16 EP EP83903370A patent/EP0125252A1/fr not_active Withdrawn
- 1983-11-16 WO PCT/CH1983/000127 patent/WO1984001899A1/fr unknown
- 1983-11-16 US US06/631,555 patent/US4619829A/en not_active Expired - Fee Related
- 1983-11-16 JP JP58503505A patent/JPS59502024A/ja active Granted
Non-Patent Citations (1)
Title |
---|
See references of WO8401899A1 * |
Also Published As
Publication number | Publication date |
---|---|
US4619829A (en) | 1986-10-28 |
JPH0564129B2 (fr) | 1993-09-14 |
JPS59502024A (ja) | 1984-12-06 |
WO1984001899A1 (fr) | 1984-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0125252A1 (fr) | Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines | |
DE69636413T2 (de) | Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe | |
Sorenson et al. | Treatment of rheumatoid and degenerative diseases with copper complexes: a review with emphasis on copper-salicylate | |
US8518460B2 (en) | Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis | |
DE3023588C2 (de) | Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens | |
EP0037488A2 (fr) | Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses | |
DE3500670A1 (de) | Diphosphonate enthaltende arzneimittel | |
WO2003099265A2 (fr) | Combinaison d'agents actifs pharmaceutiques et utilisation | |
DE3213091A1 (de) | Verwendung von femoxetin oder einem pharmazeutisch vertraeglichen salz davon zur steuerung und verminderung von appetit und gewicht | |
Spies et al. | Prednisone and Prednisolone as Therapeutic Agents: Progress Report on Their Integration into General Medical Practice | |
DE1917283C3 (de) | Herstellung antimikrobieller Präparate | |
US5376372A (en) | Analgesic and inflammation-reducing medicament | |
EP0018550B1 (fr) | Compositions pour le traitement de maladies musculaires | |
Asfora | Vitamin C in high doses in the treatment of the common cold | |
EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
DE3830333C1 (en) | Pharmaceutical composition for the treatment of the eruption caused by herpes viruses | |
RU2101015C1 (ru) | Наружное средство и способ лечения неврологических заболеваний и заболеваний опорно-двигательного аппарата с болевым синдромом и отечностью | |
DE3439805C2 (de) | Verwendung von Argininaspartat zur Behandlung der Hypotrophie | |
KR20020066242A (ko) | 관절염 치료용 생약제제 | |
DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
Martin | Thiouracil in the Treatment of Hyperthyroidism | |
DE3419686A1 (de) | Verwendung einer zusammensetzung mit therapeutischer wirksamkeit | |
Lamson | Benzoyl peroxide in the treatment of poison ivy intoxication | |
US20200281876A1 (en) | Topical Preparation for the Treatment of Arthritis and Skin Conditions | |
Dunlop | Desoxycorticosterone in Addison's Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19841017 |